Who Paid My Doc
Thanh Le
Family Medicine Alma, AR Medical Doctor
NPI 1144664384 CMS profile 1381597
937 Highway 64 E, Alma, AR 72921
General payments
$1,085
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Thanh Le of Alma, AR is reported in the CMS Open Payments database as having received $1,085 across 77 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $114 | 7 | |
| 2021 | General | $435 | 36 | |
| 2020 | General | $309 | 18 | |
| 2019 | General | $227 | 16 |
Beside peers
- Thanh Le
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Thanh Le were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Thanh Le | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $227 | $150 | $41–$543 | $163 |
| 2020 | $309 | $120 | $32–$415 | $114 |
| 2021 | $435 | $137 | $35–$551 | $132 |
| 2022 | $114 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 251 drugsPart D claims
21,495
Drug cost
$1,276,653
Branded share of claims
22.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 991 | $286,819 | |
| Xifaxan Rifaximin | Brand | 60 | $95,246 | |
| Xarelto Rivaroxaban | Brand | 335 | $92,070 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 70 | $48,601 | |
| Myrbetriq Mirabegron | Brand | 149 | $34,201 | |
| Jardiance Empagliflozin | Brand | 89 | $26,036 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 33 | $24,688 | |
| Ozempic Semaglutide | Brand | 24 | $24,529 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 54 | $22,853 | |
| Linzess Linaclotide | Brand | 37 | $21,168 |
The 10 drugs with the highest cost, of 251 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
77 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Arkansas
Related records
Family Medicine in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.